LENZ Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Chevallard Daniel R. acquired Company’s shares for reported $50017.0 on Nov 07 ’25. In the deal valued at $22.76 per share,2,198 shares were bought. As a result of this transaction, Chevallard Daniel R. now holds 5,386 shares worth roughly $0.12 million.
Then, Versant Venture Capital VI, L. sold 132,944 shares, generating $6,117,323 in total proceeds. Upon selling the shares at $46.01, the 10% Owner now owns 1,050,599 shares.
Before that, Versant Venture Capital VI, L. sold 92,030 shares. LENZ Therapeutics Inc shares valued at $4,234,695 were divested by the 10% Owner at a price of $46.01 per share. As a result of the transaction, Versant Venture Capital VI, L. now holds 764,127 shares, worth roughly $17.55 million.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Raymond James began covering LENZ with “an Outperform” recommendation on September 27, 2024. H.C. Wainwright started covering the stock on August 12, 2024. It rated LENZ as “a Buy”.
Price Performance Review of LENZ
On Friday, LENZ Therapeutics Inc [NASDAQ:LENZ] saw its stock jump 0.04% to $22.97. Over the last five days, the stock has lost -22.71%. LENZ Therapeutics Inc shares have fallen nearly -19.83% since the year began. Nevertheless, the stocks have fallen -20.44% over the past one year. While a 52-week high of $50.40 was reached on 10/02/25, a 52-week low of $16.53 was recorded on 04/09/25.
Levels Of Support And Resistance For LENZ Stock
The 24-hour chart illustrates a support level at 22.01, which if violated will result in even more drops to 21.05. On the upside, there is a resistance level at 23.93. A further resistance level may holdings at 24.89.
How much short interest is there in LENZ Therapeutics Inc?
A steep rise in short interest was recorded in LENZ Therapeutics Inc stocks on 2025-10-15, growing by 0.64 million shares to a total of 5.66 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 5.02 million shares. There was a rise of 11.25%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
